Medicines in the making
Our founding team has worked extensively in cancer R&D. Our pipeline will always reflect this hard-won experience. But cancer drug discovery is a great teacher for working on difficult problems in other disease areas, which has led us to active preclinical programs in immunology and neurology.
Programs designed to maximize patient impact
Lymphoma
TLN-121
BCL6 is a naturally occurring protein that some lymphoma cells exploit to turn off genes that could get in the way of their mutating, proliferating and surviving as cancer cells. We designed TLN-121 to remove BCL6 from cancer cells while avoiding off-target effects that could cause toxicity. We believe this drug design choice can give TLN-121 the best chance at being used in combination with other medicines useful in the treatment of lymphoma.
TLN-254
EZH2 is a naturally occurring protein that helps cells regulate which genes are translated into proteins. It is overexpressed and even mutated in many cancers. We in-licensed TLN-254 from Jiangsu Hengrui Pharmaceuticals for territories excluding Greater China, where the medicine is marketed as Airuijing™ (zeprumetostat or SHR2554) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma who have received at least one prior line of systemic therapy. We in-licensed TLN-254 as a potential combination partner for TLN-121, given EZH2's potential to mechanistically complement BCL6 biology in lymphoma.
On June 2, 2026, the FDA placed a partial clinical hold on the TLN-254 monotherapy Phase 1 clinical trial and on the TLN-254 combination arm of the TLN-121 Phase 1 trial due to concerns regarding the potential for secondary malignancies in patients treated with the EZH2 inhibitor class of drug. Patients in these trials may continue receiving TLN-254 if they are deriving a clinical benefit, but enrollment to receive TLN-254 in these studies has been paused. We are working with the FDA to address the partial hold.
Solid Tumors
TLN-372
Approximately 1 in 4 adult cancers harbors an alteration in the KRAS protein. There are FDA-approved medicines for G12C cancers, a subset of KRAS tumors, though KRAS has been a historically difficult oncology target to drug. Our chemists went “back to basics” to innovate rather than follow, producing a compound that is designed to achieve deep and sustained pan-KRAS target inhibition.
About Treeline’s Investigational Medicines
We are focused on developing and carefully studying new therapies with the hope of helping patients. Right now, our therapies are investigational, which means they have not yet been approved as safe and effective by the U.S. Food and Drug Administration (FDA) or other health authorities. Currently, patients can access these investigational therapies only by taking part in one of our clinical trials.
To learn more about these investigational therapies and how to access them, please talk with your provider or visit ClinicalTrials.gov.